Cargando…

Effects of MS disease-modifying therapies on responses to vaccinations: A review.

BACKGROUND: : Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciotti, John Robert, Valtcheva, Manouela V., Cross, Anne Haney
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395588/ https://www.ncbi.nlm.nih.gov/pubmed/32769063 http://dx.doi.org/10.1016/j.msard.2020.102439

Ejemplares similares

Protein kinase Cδ mediates histamine-evoked itch and responses in pruriceptors
por: Valtcheva, Manouela V, et al.
Publicado: (2015)

How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?
por: Giovannoni, Gavin
Publicado: (2022)

Metabotropic Glutamate Receptor 2/3 (mGluR2/3) Activation Suppresses TRPV1 Sensitization in Mouse, But Not Human, Sensory Neurons
por: Sheahan, Tayler D., et al.
Publicado: (2018)

Perspectives and experiences with COVID-19 vaccines in people with MS
por: Ciotti, John R., et al.
Publicado: (2022)

Effect of vitamin D on MS activity by disease-modifying therapy class
por: Rotstein, Dalia L., et al.
Publicado: (2015)

Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
por: Holroyd, Kathryn B., et al.
Publicado: (2022)

COVID-19 and MS disease-modifying therapies
por: Berger, Joseph R., et al.
Publicado: (2020)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies
por: Sormani, Maria Pia, et al.
Publicado: (2021)

Outcome of MS relapses in the era of disease-modifying therapy
por: Stoppe, Muriel, et al.
Publicado: (2017)

Disease-modifying therapies alter gut microbial composition in MS
por: Katz Sand, Ilana, et al.
Publicado: (2018)

The COVID-19 pandemic and the use of MS disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
por: McFaul, Derek, et al.
Publicado: (2021)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
por: Kister, Ilya, et al.
Publicado: (2022)

Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies
Publicado: (2023)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Drugs, bugs, and MS: The interplay between disease-modifying therapy and gut microbiota
por: Mangalam, Ashutosh K.
Publicado: (2018)

Quality of life should be the primary outcome for disease modifying therapy trials in MS—No
por: Strijbis, EMM, et al.
Publicado: (2023)

Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
por: Smith, Tyler E, et al.
Publicado: (2022)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis
por: Jain, Vikramraj K., et al.
Publicado: (2017)

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
por: Cabreira, Verónica, et al.
Publicado: (2021)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
por: Manouchehri, Navid, et al.
Publicado: (2022)

LC-MS/MS Determination of Modified Nucleosides in The Urine of Parkinson’s Disease and Parkinsonian Syndromes Patients
por: Gątarek, Paulina, et al.
Publicado: (2020)

Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
por: Largey, Fabienne, et al.
Publicado: (2019)

Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
por: Maguire, Cole, et al.
Publicado: (2020)

Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective
por: Corea, Francesco, et al.
Publicado: (2021)

Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register
por: D’Amico, Emanuele, et al.
Publicado: (2021)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Astrocytes gate Hebbian synaptic plasticity in the striatum
por: Valtcheva, Silvana, et al.
Publicado: (2016)

Control of Long-Term Plasticity by Glutamate Transporters
por: Valtcheva, Silvana, et al.
Publicado: (2019)

Simultaneous Quantitation of Isoprenoid Pyrophosphates in Plasma and Cancer Cells Using LC-MS/MS
por: Chhonker, Yashpal S., et al.
Publicado: (2018)

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022)

Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population
por: Ng, Huah Shin, et al.
Publicado: (2022)

COVID-19 vaccines and multiple sclerosis disease-modifying therapies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Long non-coding RNA SeT and miR-155 regulate the Tnfα gene allelic expression profile
por: Stathopoulou, Chrysoula, et al.
Publicado: (2017)

Detecting diagnostic features in MS/MS spectra of post-translationally modified peptides
por: Geiszler, Daniel J., et al.
Publicado: (2023)

Gene variants of adhesion molecules act as modifiers of disease severity in MS
por: Dardiotis, Efthimios, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8bm9r04fupaj454qj28koork06